- Home
- ALZN vs KZIA Comparison
ALZN vs KZIA Comparison
Compare ALZN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- KZIA
- Stock Information
- Founded
- ALZN 2016
- KZIA 1994
- Country
- ALZN United States
- KZIA Australia
- Employees
- ALZN N/A
- KZIA N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ALZN Health Care
- KZIA Health Care
- Exchange
- ALZN Nasdaq
- KZIA Nasdaq
- Market Cap
- ALZN 8.2M
- KZIA 9.0M
- IPO Year
- ALZN 2021
- KZIA 1999
- Fundamental
- Price
- ALZN $2.50
- KZIA $7.94
- Analyst Decision
- ALZN Strong Buy
- KZIA Strong Buy
- Analyst Count
- ALZN 1
- KZIA 2
- Target Price
- ALZN $45.00
- KZIA $14.00
- AVG Volume (30 Days)
- ALZN 88.6K
- KZIA 137.3K
- Earning Date
- ALZN 09-10-2025
- KZIA 11-14-2025
- Dividend Yield
- ALZN N/A
- KZIA N/A
- EPS Growth
- ALZN N/A
- KZIA N/A
- EPS
- ALZN N/A
- KZIA N/A
- Revenue
- ALZN N/A
- KZIA $1,549,158.00
- Revenue This Year
- ALZN N/A
- KZIA N/A
- Revenue Next Year
- ALZN N/A
- KZIA $49.25
- P/E Ratio
- ALZN N/A
- KZIA N/A
- Revenue Growth
- ALZN N/A
- KZIA 248983.08
- 52 Week Low
- ALZN $2.06
- KZIA $2.86
- 52 Week High
- ALZN $17.10
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- ALZN 52.23
- KZIA 48.43
- Support Level
- ALZN $2.33
- KZIA $7.60
- Resistance Level
- ALZN $2.64
- KZIA $8.28
- Average True Range (ATR)
- ALZN 0.13
- KZIA 0.51
- MACD
- ALZN 0.04
- KZIA 0.03
- Stochastic Oscillator
- ALZN 66.10
- KZIA 30.88
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.